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Introduction
The drug 2-(3-Benzoylphenyl)-propionic acid, commonly known 
as ketoprofen (KPF), belongs to the non-steroidal anti-inflammatory 
drugs (NSAIDs) which not only produce good analgesia but also exerts 
antipyretic effects [1]. KPF also exhibits anti-inflammatory properties 
via inhibition of cyclooxygenase 1 and 2 (COX 1 and COX 2) 
enzymes reversibly, which decreases production of pro-inflammatory 
prostaglandin and thromboxane precursors [2].
This drug not only is available for oral administration but also as 
gel and delivery system patch (TDS), for its topical application. Topical 
NSAIDs offer the advantage of local, enhanced drug delivery to affected 
tissues with a reduced incidence of systemic adverse events [3]. KPF has 
been shown to be well absorbed orally with peak plasma concentrations 
occurring within 1 hour and it has a short half-life of approximately 
2 h. It is 99% bound plasma proteins, and 85-99% of KPF and its 
metabolites are excreted in the urine rather than the feces [4].
Although the oral bioavailability and pharmacokinetic 
characteristics of KPF have been well described in clinical studies 
previously [5,6], they have not reported the bioequivalence of a newly 
developed generic product, in Latin American population. Here, 
we compared the bioavailability between the test and its reference 
product in healthy adult human male subjects using high-pressure 
liquid chromatography - tandem mass spectrometry (HPLC-MS/MS). 
The method was developed and validated in the Biopharmaceutical 
Research Center DominguezLab.
Material and Methods
Formulations and participants
The present study was designed to evaluate Flogofin® (from 
Laboratorio Chile S. A., Chile, as test, lot no. 12093261; expiration 
date 09/2015) and Profenid® (from Sanofi-Aventis de Venezuela S.A., 
Venezuela, as reference, lot no. 1VE0243; expiration date 10/2015) of 
KPF 50 mg capsule formulations.
Twenty four healthy Latin Americans male volunteers participated 
in this study, which was conducted at the Biopharmaceutical Research 
Center DominguezLab. The ages of subjects were between 18-46 years 
old (25 ± 7 years), the body weights of subjects were between 54-87 kg 
(71 ± 9 kg) and the heights of the subjects were between 166-183 cm (174 
± 5 cm). Subjects were selected after screened by physical examination 
and clinical laboratory tests including renal and liver functions, routine 
blood (Hb, Ht, RBC, platelet, WBC, BUN, total bilirubin, glucose 
fasting, total protein albumin, alkaline phosphatase, sGPT, sGOT), and 
urine analysis (specific gravity, color, pH, sugar, albumin, bilirubin, 
RBC, WBC, cast). Subjects were excluded if they were smoker, have 
a history of any illness of renal and liver, history of alcohol or other 
medications for long period of time. The consumption of alcohol or 
beverages and food, containing xanthines was not permitted for the 
volunteers, 48 h prior to the study and after drug administration, 
until the last blood sample was collected in the respective study phase. 
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Subjects were instructed to abstain from taking any medication for at 
least 2 weeks prior to and during the study period.
Informed consent was approved by the Institutional Ethical 
Committee and it was obtained from the subjects after explaining the 
nature and purpose of the study. The study protocols were approved 
by the Public Health Institute of Chile (ISP of República de Chile).
The present study was also conducted in accordance with ICH Good 
Clinical Practice (GCP), all applicable subject privacy requirements, 
and the guiding principles of the 2008 Declaration of Helsinki.
The selection and inclusion of patients according to eligibility 
criteria were be performed following DominguezLab Standard 
Operative Procedure PG-005-CLI-002.
Study design
This was a single-dose, randomized-sequence, open label, 2-way 
crossover bioequivalence study. After an overnight fast for 10 h and 
signing the informed-consent form, the volunteers received a single 200 
mg dose (4 capsules × 50 mg) of the test or reference formulation with 
240 mL of water in random order, with the 2 study periods separated by 
a 1 week washout period. The standardized lunch and dinner (8 kcal/
kg body weight; 55% carbohydrate, 15% protein, and 30% fat) were 
provided at 4 and 9 h after administration, respectively. Water intake 
was allowed 2 h after the dose; water, lunch and dinner were given to all 
volunteers according to a time schedule. 
The washout period was determined based on 5 to 7 times the 
T1/2 of KPF (2 h). The volunteers were confined to the center 12 h 
before drug administration and for 24 h after administration. The 
volunteers were under continuously monitored by medical supervision 
throughout the confinement period of the study. Approximately 8 mL 
of blood for KPF assay was drawn into heparinized tubes through an 
indwelling cannula before (0 h) and at 0.17 h, 0.33 h, 0.50 h, 0.75 h, 1 h, 
1.17 h, 1.50 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h and 24 hours 
after drug administration. The plasma was separated by centrifugation 
at 3000 ×g for 10 minutes at room temperature (20°C), followed by 
direct transfer into 2 mL polypropylene tubes and storage frozen at 
-20°C until analysis. After a 1 week washout period, the study was 
repeated in the same manner to complete the cross-overdesign.
Tolerability
In this study, all the volunteers were continuously and carefully 
monitored. Tolerability was assessed by monitoring vital signs 
(temperature, blood pressure, heart rate, and respiratory rate) at 
baseline before dosing and during the study by a qualified nurse. 
Laboratory tests (hematology, urinalysis, and blood biochemistry), 
physical examinations, and ECGs were also performed at baseline and 
at completion of the study.
Adverse events (AEs) were assessed at the time of each blood draw 
using direct observation, spontaneous reporting, and nonspecific 
questioning. Any undesirable sign, symptom, or medical condition 
occurring after the start of the study was recorded regardless of the 
suspected relationship to the study drug. AEs were graded as mild, 
moderate, or severe, and their relationship to the study drug was 
determined by the study physicians as not related, probably not related, 
uncertain, possibly related, probably related, or definitely related. 
The physicians who were responsible for determining the clinical 
significance of AEs were blinded to the treatment.
Chemicals and reagents
KPF (USP, LOT H1H247, 99.8% w/w) and KPF-d3 (TLC, Canada 
LOT 1038-047 A1, 99.9% w/w) were supplied by the pharmaceutical 
industry. Water and Acetonitrile (ACN) were purchased from Carlo 
Erba, France and formic acid was purchased from Sigma-Aldrich, 
Germany. All reagents were analytic grade or above.
Sample collection
Samples were obtained from healthy volunteers of Dominguez 
Lab, according to Standard Operative Procedure of Dominguez Lab 
P-004-PTG-009: “Samples Identification and Preparation”. Briefly, 
for sampling a catheter system (BD Saf-T-IntimaTM, BD Vacutainer®) 
was used and syringes of 5 mL. The blood sample was collected into 
heparinized polypropylene 4 mL tubes (NAHEP PLH 13X75 4.0 PLBL 
GN, BD Vacutainer®, Broken Bow NE 68822 US) and centrifuged at 
3000×g for plasma separation. Aliquots of 1 mL were preserved in 
polypropylene 2 mL cryovials and frozen at -20°C ± 5°C until analysis.
Bioanalysis of plasma samples
Plasma KPF samples were analyzed by using a validated HPLC-
MS/MS system: Quantitation was achieved by measurement of the 
peak area ratio of the drug to the KPF-d3 as internal standard (IS). 
Stock solutions (1 mg/mL) were prepared by dissolving an appropriate 
amount of each compound in ACN. Working solutions were prepared 
daily by dilutions of the stock solutions with ACN. Calibration curves of 
KPF were prepared by spiking blank human plasma in a concentration 
range of 48-19294 ng/mL.
Samples and Quality Controls (QC´s) were thawed at room 
temperature on the day of analysis: Aliquots of 300 µL sample or QC’s 
were mixed with 200 µL of IS working solution (at 7 µg/mL). A 700 μL 
aliquot of ACN was added in order to protein precipitation and vortex 
mixed for 30 s. After samples were centrifuged at 3000 ×g for 5 min., 
a volume of 500 μL of the supernatant was diluted by adding 1000 μL 
of water. An aliquot (30 μL) was injected into a Hypersil GOLD C18 
analytical column (150 x 2.1 mm i.d., 3 µm). A mobile phase of 0.1% 
formic acid in water/ACN (40:60, v/v) was pumped isocratically at a 
flow rate of 0.30 mL/min. Under these conditions, typical retention 
times were 2.3 min for KPF and IS and the runtime was 4.0 min. 
Detection and quantification were achieved by using high performance 
liquid chromatography (HPLC) coupled to a triple-quadrupole 
mass spectrometer (VARIAN 1200L) with electrospray ionization 
interface in positive mode. The mass spectrometer was used in the 
multiple reaction monitoring (MRM) mode and the m/z transition for 
quantification collected in positive mode were 254.6 → 208.9 and 257.6 
→ 211.8 for KPF and KPF-d3 respectively.
The proposed analytical method was evaluated in terms of linearity, 
specificity, accuracy and precision intra-day and inter-day, LOQ, 
recovery, and stability. To assess stability, QC´s plasma samples (104, 
8104 and 16208 ng/mL) were subjected to short-term room stability 
(6 h), post processing stability (12 h remain at the auto-sampler 
temperature), freeze-and-thaw stability (after 3 cycles of freezing 
(-20ºC) and thawing (room temperature), and long-term stability (60 
days at -20°C).
Pharmacokinetics and statistical analysis
To compare the bioavailability (in accordance with the criteria for 
bioequivalence [the rate and extent to which the active ingredient or 
active moiety is absorbed from a drug product and becomes available at 
the site of action] established by the US Food and Drug Administration, 
in vivo bioequivalence guidelines) [7] of the formulations tested, the 
following pharmacokinetic (PK) parameters were calculated using 
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Flogofin® are comparable to those produced by Profenid®. Analysis of 
variance (ANOVA) for these parameters, after log-transformation of 
the data, showed no statistically significant difference between the two 
formulations either in periods, formulations or sequence, having P 
values greater than 0.05. Table 2 shows the 90% CIs of the ratios (test/
reference) for the log-transformed values of Cmax (as an index of rate 
of absorption), AUC0–24h, and AUC0–∞ (as an index of the extent of 
absorption) and the probability of exceeding the limits of acceptance 
(Schuirmann’s two 1-sided t tests) for KPF capsules. The 90% CIs for 
the corresponding ratios of Cmax, AUC0–24h, and AUC0–∞ were within the 
80% to 125% range. All P values were <0.05.
Conclusion
These results suggested that reference and test formulations (KPF 
capsules) were not statistically different in terms of their PK parameters 
(Cmax, AUC0–t and AUC0–∞). In addition, Tmax and T1/2 values had not 
clinically important differences between them (based on means and 
standard deviations). Considering that all 90% CIs of the ratios of the 
a validated PK software, Win Nonlin version 6.02 (Pharsight Corp. 
Mountain View, CA): area under the curve from time zero to the last 
measurable KPF concentration in plasma (AUC0-24), using the linear 
trapezoidal rule; (AUC0-∞), calculated as the sum of AUC0-24 plus Clast/
Ke (where Clast is the last measurable plasma concentration, and Ke 
is the terminal rate constant of elimination); maximum measured 
concentration of KPF (Cmax); time to maximum plasma concentration 
(Tmax); and terminal elimination half-life (T1/2). After logarithmic 
transformation, AUC0-∞, AUC0-24and Cmax values were subjected to 
analysis of variance (ANOVA). The bioequivalence between the two 
formulations was evaluated based on the 90% CI transformed back 
for the geometric mean ratios of AUC0-∞, AUC0-24 and Cmax, which 
were within acceptance range of 80-125% according to the local and 
international guidelines [7-11].
Results and Discussion
Analytical performance and method validation
Calibration curves showed a satisfactory linearity within the 
concentration range of: 48-19294 ng/mL (r = 0.999). The LOQ was 48 
ng/mL and was defined as the lowest concentration in the calibration 
curve that can be measured with acceptable accuracy and precision 
[12-14]. The LOQ was considerably low compared with other works 
[15,16] and probably this was attributed to the LC-MS/MS technology 
which allowed more reliable measurements.
Specificity was assessed in six different batches of plasma samples 
by analyzing blanks and spiked samples at LOQ levels. No significant 
chromatographic signals of endogenous KPF were observed for any 
plasma batches at the target analytes retention times (KPF and IS). The 
intra-day and inter-day precision (RSD%) was less than 3.0 and 7.8%, 
respectively. Accuracy, evaluated as relative error (RE), was within 12% 
for the intra-day and 7% for the inter-day. The extraction recoveries of 
KPF were 87%, 90% and 100% in the concentrations of 116, 8333 and 
18333 ng/mL respectively. Post-processing, freeze-and-thaw, short-
term and long-term stability tests proved that KPF, did not show any 
significant degradation at the temperatures and time periods specified. 
The analytical methods to determine KPF concentrations in human 
plasma herein described were in agreement with the international 
guideline [11-13].
Tolerability
All the subjects successfully completed the study according to 
the protocol, and both KPF formulations were well tolerated at the 
administered doses. Only one volunteer refereed mild acid sensitive 
syndrome, probably related to the drug, and it was resolved with 
ranitidine. All biochemical parameters did not present any clinical 
relevant alterations. No other adverse effects were reported or observed.
Pharmacokinetic parameters mean
The mean concentration-time profiles for KPF for the test and 
reference formulations are shown in Figure 1, and they were closely 
similar and superimposable. The pharmacokinetic parameters 
(AUC0–24h and AUC0–∞, Cmax, Tmax, T1/2 and Ke) for the both KPF 
formulations are shown on Table 1. Peak concentrations of 21.58 
± 6.69 ng/mL and 21.65 ± 8.48 ng/mL for KPF were attained at 
1.10 and 1.49 h after drug administration for the test (Flogofin®) 
and reference (Profenid®) products, respectively, and then declined 
rapidly and remained detectable until 24 h. The mean and standard 
deviation of AUC0–24h, AUC0–∞ and Cmax of the two products did not 
differ significantly, suggesting that the plasma profiles generated by 
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Figure 1: Plasma mean concentrations of 200 mg KPF versus time profile 
obtained after oral administration of single dose (4 capsules × 50 mg) of two 
brands (Flogofin® or Profenid®) to 24 volunteers.
Pharmacokinetic 
parameter
Flogofin® 
(Test)
Profenid® 
(Reference)
AUC0-24 ([μg h]/mL) 52.21 ± 1.15 50.68 ± 10.52
AUC0-∞ ([μg h]/mL) 52.38 ± 11.51 50.84 ± 10.57
Cmax(μg/mL) 21.58 ± 6.69 21.65 ± 8.48
Tmax(h) 1.10 ± 0.53 1.49 ± 1.00
T1/2 (h) 3.62 ± 0.75 3.54 ± 0.59
Ke(h
-1) 0.20 ± 0.05 0.20 ± 0.05
Table 1: Pharmacokinetic parameters obtained from 24 volunteers after oral 
administration of 200 mg ketoprofen (4 capsules x 50 mg) formulation (Mean ± 
Standard deviation).
Probability of Exceeding
Limits of Acceptance
Ratio,
Parameter %Reference 90%CI <80% >125%
Ln Cmax % ratio 102.4 89.3-117.5 <0.00268 <0.01039
Ln AUC0–t % ratio 103.1 98.1-108.4 <0.00000 <0.00000
Ln AUC0–∞ % ratio 103.2 98.2-108.4 <0.00000 <0.00000
Table 2: Comparison of 90% CIs of natural log-transformed ratios of Cmax, ln AUC0–
24, and ln AUC0–∞, the probability of exceeding the limits of acceptance, and power 
test in KPF capsules (4 capsules × 50 mg).
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pharmacokinetic parameters (Cmax, AUC0–24h and AUC0–∞) were within 
the predetermined range of bioequivalence (80%-125%) with P <0.05, 
results of both studies satisfied the accepted regulatory requirements to 
assume bioequivalence.
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